国产吉西他滨联合顺铂治疗晚期非小细胞肺癌的临床观察  

Clinical research on combined chemotherapy of gemcitabine and cisplatin in the treatment of non-small cell lung cancer

作　　者：彭文娟[1] 方浩徽 

机构地区：[1]安徽省肺科医院呼吸内科,安徽合肥230022

出　　处：《安徽医药》2011年第9期1152-1153,共2页Anhui Medical and Pharmaceutical Journal

摘　　要：目的观察国产吉西他滨（GEM）联合顺铂（DDP）治疗晚期非小细胞肺癌的近期疗效、毒副反应、中位生存期及耐受性。方法国产吉西他滨1 000 mg.m-2,静脉滴注30 min,第1、8天;顺铂60~70 mg·m-2,静脉滴注,分3~4 d应用,28 d为一个周期,治疗39例晚期非小细胞肺癌患者。结果 39例患者共化疗112周期,完全缓解CR 0,部分缓解PR 15例（38.5%）,稳定SD 14例（35.6%）,进展PD 10例（25.6%）,总有效率38.5%,疾病控制率（CR＋PR＋SD）74.4%,中位疾病进展时间5.4个月,中位生存期10.6个月。毒副作用主要为粒细胞减少、血小板下降、胃肠道反应,均可耐受。结论吉西他滨联合顺铂治疗非小细胞肺癌的疗效肯定且患者耐受性较好。Aim To evaluate the efficacy,side-effect,median survival duration and toxicity of gemcitabine（GEM）combined with cisplatin（DDP）in the treatment of advanced non-small-cell lung cancer.Methods Thirty-nine patients with advanced non-small-cell lung cancer were treated with gemcitabine 1000 mg·m-2 on d1、8,cisplatin 60～70 mg·m-2 on d1-3.The regimen was repeated every 28 days.All patients received two or more cycles.Results Thirty-nine patients were evaluated after 2 to 6 cycles of chemotherapy.None achieved CR and 15 cases achieved PR.The overall response rate（ORR）was 38.5% and the disease control rate（DCR）was 74.4%.The median time to progression（TTP）was 5.4 months,and median overall survival（OS）was 10.6 months.The most common toxicities were neutropenia,thrombocytopenia,anaemia and fatigue.These toxicities were well-tolerated.Conclusion Gemcitabine plus cisplatin is an effective and well tolerated regimen for non-small-cell lung cancer.

关 键 词：晚期非小细胞肺癌 化疗 吉西他滨 顺铂 

分 类 号：R734.2[医药卫生—肿瘤]